Breaking News: Ebola

Filters close
14-Feb-2024 7:05 AM EST
Music Exposes Listeners to Alcohol References, Potentially Influencing Drinking
Research Society on Alcoholism

At least one in four contemporary songs references alcohol, according to an analysis of multiple studies that hints at the effects of music exposure on listeners’ drinking.

Newswise: Erica Ollmann Saphire wins 2023 Pantheon Award from California Life Sciences
Released: 3-Nov-2023 1:05 PM EDT
Erica Ollmann Saphire wins 2023 Pantheon Award from California Life Sciences
La Jolla Institute for Immunology

The award recognizes Saphire's leadership and innovative research toward addressing the urgent need for effective antibody therapeutics against COVID-19 and viral threats such as Ebola and Lassa virus.

Newswise: Dr. Anthony Fauci to be awarded 2024 Inamori Ethics Prize by Inamori International Center for Ethics and Excellence
24-Oct-2023 12:05 PM EDT
Dr. Anthony Fauci to be awarded 2024 Inamori Ethics Prize by Inamori International Center for Ethics and Excellence
Case Western Reserve University

The Inamori International Center for Ethics and Excellence at Case Western Reserve University will award Dr. Anthony Fauci, a physician, immunologist, and infectious disease expert, with the 2024 Inamori Ethics Prize.

Released: 18-Sep-2023 9:00 AM EDT
Research analyzes relationship between agriculture, emergence of new diseases
Indiana University

Researchers propose a new way of understanding how diseases spread between animals and humans, by focusing on the effect that agriculture, ecological and sociopolitical factors have on disease emergence and transmission.

Newswise: A new look inside Ebola's
Released: 9-Aug-2023 4:05 PM EDT
A new look inside Ebola's "viral factories"
La Jolla Institute for Immunology

The study, led by scientists at La Jolla Institute for Immunology (LJI), reveals the inner workings of viral factories, clusters of viral proteins and genomes that form in host cells.

Newswise: Caring for the Community During the Next Pandemic
Released: 20-Jun-2023 10:05 AM EDT
Caring for the Community During the Next Pandemic

Later this summer, staff members at Cedars-Sinai Marina del Rey Hospital will spring into action when a pretend patient comes to the Emergency Department with symptoms of a virus like Ebola, one of the deadliest, most infectious diseases on the planet.

Released: 12-May-2023 3:30 PM EDT
Immigration Nation: Research and Experts

Title 42, the United States pandemic rule that had been used to immediately deport hundreds of thousands of migrants who crossed the border illegally over the last three years, has expired. Those migrants will have the opportunity to apply for asylum. President Biden's new rules to replace Title 42 are facing legal challenges. Border crossings have already risen sharply, as many migrants attempt to cross before the measure expires on Thursday night. Some have said they worry about tighter controls and uncertainty ahead. Immigration is once again a major focus of the media as we examine the humanitarian, political, and public health issues migrants must go through.

Newswise:Video Embedded live-event-for-april-21-sleeping-pill-reduces-levels-of-alzheimer-s-proteins
Released: 21-Apr-2023 3:10 PM EDT
TRANSCRIPT AND VIDEO AVAILABLE Live Event for April 21: Sleeping pill reduces levels of Alzheimer’s proteins

Researcher will discuss the study which involved a sleeping aid known as suvorexant that is already approved by the Food and Drug Administration (FDA) for insomnia, hints at the potential of sleep medications to slow or stop the progression of Alzheimer’s disease.

Released: 7-Feb-2023 9:00 AM EST
Speakers Announced for #DiscoverBMB
American Society for Biochemistry and Molecular Biology (ASBMB)

Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, will feature award lectures by high-profile speakers discussing noteworthy research, education and diversity initiatives. The meeting will take place March 25–28 in Seattle.

Newswise: LJI scientists uncover the structure and function of Inmazeb, the first FDA-approved drug for Ebola virus infection
Released: 30-Jan-2023 4:30 PM EST
LJI scientists uncover the structure and function of Inmazeb, the first FDA-approved drug for Ebola virus infection
La Jolla Institute for Immunology

Inmazeb (REGN-EB3), developed by Regeneron, is a three-antibody cocktail designed to target the Ebola virus glycoprotein. The drug was first approved for clinical use in October 2020, but its exact mechanism of action has remained unclear.

Newswise: Say Ahhh! Fruit Bat Gets a Check-up in the Republic of Congo
Released: 24-Jan-2023 4:55 PM EST
Say Ahhh! Fruit Bat Gets a Check-up in the Republic of Congo
Wildlife Conservation Society

The Wildlife Conservation Society (WCS) released an image of scientists taking a swab from a straw-colored fruit bat (Eidolon helvum) to test it for zoonotic diseases such as the Ebola virus.

Newswise: MedStar Washington Hospital Center Opens Biocontainment Unit to Care for Patients Who Contract Highly Infectious Diseases
Released: 19-Jan-2023 11:00 AM EST
MedStar Washington Hospital Center Opens Biocontainment Unit to Care for Patients Who Contract Highly Infectious Diseases
MedStar Washington Hospital Center

MedStar Washington Hospital Center has opened a new state-of-the-art Biocontainment Unit (BCU) to care for patients who contract highly infectious diseases. Located near the Emergency Room, the new multi-purpose 15-bed unit will be used primarily for observation and flexed for respiratory isolation and further flexed to care for patients with highly contagious conditions, such as Ebola.

Released: 19-Dec-2022 3:35 PM EST
Texas Biomed at forefront of Sudan ebolavirus biomedical R&D
Texas Biomedical Research Institute

A Sudan ebolavirus vaccine and antibody therapeutic tested at Texas Biomedical Research Institute have been sent to Uganda as part of efforts to control the outbreak there.

Newswise: Dr. Fauci reflects on the perpetual challenge of infectious diseases
Released: 28-Nov-2022 12:20 PM EST
Dr. Fauci reflects on the perpetual challenge of infectious diseases
NIH, National Institute of Allergy and Infectious Diseases (NIAID)

Once considered a potentially static field of medicine, the discipline of studying infectious diseases has proven to be dynamic as emerging and reemerging infectious diseases present continuous challenges, Anthony S. Fauci, M.D., writes in a perspective in The New England Journal of Medicine.

Newswise: Bobby Brooke Herrera Joins Rutgers Global Health Institute as Principal Faculty Member
Released: 28-Oct-2022 2:45 PM EDT
Bobby Brooke Herrera Joins Rutgers Global Health Institute as Principal Faculty Member
Rutgers University-New Brunswick

Research scientist Bobby Brooke Herrera, renowned for developing tools to accelerate diagnosis and treatment of infectious diseases such as COVID-19, has joined Rutgers Global Health Institute.

Newswise: Medical Researcher Aims to Glimpse Inside the “Minds” of Viral Killers
Released: 27-Sep-2022 10:05 AM EDT
Medical Researcher Aims to Glimpse Inside the “Minds” of Viral Killers
Rutgers University-New Brunswick

Ricardo Rajsbaum understands killers. Like a criminal investigator tracking prey, the Rutgers virologist spends his days researching the enemy. Rather than obsessing over a madman’s next move, however, Rajsbaum’s focus is on the microscopic viruses that infect human cells – sometimes with deadly consequences.

Released: 1-Sep-2022 4:05 PM EDT
Individual risk-factor data could help predict the next Ebola outbreak, new study shows
Lehigh University

Several years ago, a team of scientists at Lehigh University developed a predictive model to accurately forecast Ebola outbreaks based on climate-driven bat migration.

Newswise: Developing Antivirals for Pandemic-Level Viruses
Released: 10-Aug-2022 11:30 AM EDT
Developing Antivirals for Pandemic-Level Viruses
University of Illinois Chicago

Researchers at the University of Illinois Chicago are working with the National Institutes of Health and University of Minnesota to establish a center for antiviral drug development for pandemic-level viruses, including Ebola and SARS-CoV-2.

Newswise: LJI Scientists Discover Clue to Stopping Lassa Virus Infection
Released: 19-Jul-2022 2:10 PM EDT
LJI Scientists Discover Clue to Stopping Lassa Virus Infection
La Jolla Institute for Immunology

In a new study, researchers show how a critical Lassa virus protein, called polymerase, drives infection by harnessing a cellular protein in human hosts. Their work suggests future therapies could target this interaction to treat patients.

Newswise: Viruses of a Feather
Released: 12-Jul-2022 5:05 AM EDT
Viruses of a Feather
Kyoto University

Helical nucleocapsids in infected cells are composed of Marburg viral genomic RNA and nucleoproteins, or NPs, that are structurally similar to those of the Ebola virus. Future drug development may be possible based on the targeting of nucleocapsid formation, which may inhibit the Marburg virus' ability to replicate.

Newswise: Rapid Ebola Diagnosis May Be Possible with New Technology
7-Jun-2022 2:05 PM EDT
Rapid Ebola Diagnosis May Be Possible with New Technology
Washington University in St. Louis

A new tool can quickly and reliably identify the presence of Ebola virus in blood samples, according to a study by researchers at Washington University School of Medicine in St. Louis and colleagues at other institutions.

Newswise: Targeting a human protein may stop Ebola virus in its tracks
Released: 22-Mar-2022 12:15 PM EDT
Targeting a human protein may stop Ebola virus in its tracks
La Jolla Institute for Immunology

Ebola virus polymerase hijacks a cellular protein called GSPT1. An experimental drug that targets GSPT1 for degradation can also halt Ebola virus infection in human cells.

Newswise:Video Embedded promising-antibody-cocktail-takes-on-ebola-virus-and-its-deadly-cousin
15-Mar-2022 2:10 PM EDT
Promising antibody cocktail takes on Ebola virus—and its deadly cousin
La Jolla Institute for Immunology

The team's latest study, published in Cell, shows that two clever human antibodies can target two ebolavirus species at once: Ebola virus and Sudan virus. These two species are responsible for the biggest, deadliest outbreaks. The new report suggests researchers could combine these two potent antibodies to make a powerful antiviral therapy.

Newswise: Ebola Vaccine Being Used in Congo Produces Lasting Antibody Response, Study Finds
Released: 8-Feb-2022 5:10 PM EST
Ebola Vaccine Being Used in Congo Produces Lasting Antibody Response, Study Finds
UCLA Fielding School of Public Health

A new study by UCLA researchers and colleagues demonstrates that the Ebola vaccine known as rVSVΔG-ZEBOV-GP results in a robust and enduring antibody response among vaccinated individuals in areas of the Democratic Republic of Congo (DRC) that are experiencing outbreaks of the disease. Among the more than 600 study participants, 95.6% demonstrated antibody persistence six months after they received the vaccine. The study is the first published research examining post–Ebola-vaccination antibody response in the DRC, a nation of nearly 90 million. While long-term analyses of the study cohort continue, the findings will help inform health officials’ approach to vaccine use for outbreak control, the researchers said.

Released: 14-Jan-2022 1:35 PM EST
Researchers identify a set of cellular receptors in humans and other species for the eastern equine encephalitis virus, other members of the alphavirus family
Harvard Medical School

• Researchers have identified a set of receptors shared across human, mosquito, and other animal cells for the eastern equine encephalitis virus (EEEV) and two related viruses, a crucial first step for developing preventive and curative treatments. • In experiments with cells and mouse models with a related virus, the scientists were able to prevent infection and disease progression using decoy molecules to hamper viral entry into cells. • In a 2019 outbreak of eastern equine encephalitis (EEE, or triple E) in New England, 30 percent of infected people died and half of those who survived had long-term neurologic damage. • Done between major outbreaks, this type of research into highly pathogenic viruses with pandemic potential can help improve preparedness for future outbreaks.

28-Sep-2021 1:30 PM EDT
Gene Found in Monkeys and Mice Could Work as a New Type of Antiviral to Block HIV, Ebola, and Other Deadly Viruses in Humans
University of Utah Health

A nationwide team of researchers, led by scientists at University of Utah Health and The Rockefeller University, has determined how a genetic mutation found in mice and monkeys interferes with viruses such as HIV and Ebola. They say the finding could eventually lead to the development of medical interventions in humans.

Released: 14-Sep-2021 2:15 PM EDT
Proteins that outwit emerging and re-emerging viruses
Ohio State University

A family of proteins best known for their role in diminishing HIV infectivity may have the goods to outwit other emerging and re-emerging viruses, scientists have found.

Released: 19-Aug-2021 3:00 PM EDT
VIDEO AND TRANSCRIPT AVAILABLE: Breakthrough Cases and COVID Boosters: Live Expert Panel for August 18, 2021

Expert Q&A: Do breakthrough cases mean we will soon need COVID boosters? The extremely contagious Delta variant continues to spread, prompting mask mandates, proof of vaccination, and other measures. Media invited to ask the experts about these and related topics.

Released: 15-Jul-2021 9:00 AM EDT
Global Virus Network (GVN) Adds Senegal’s IRESSEF As Newest Member to Mitigate Viral Threats
Global Virus Network

The Global Virus Network (GVN), representing 63 Centers of Excellence and 11 Affiliates in 34 countries comprising foremost experts in every class of virus causing disease in humans, and the Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation [Institute for Health Research, Epidemiological Surveillance and Training], or the IRESSEF, announced the addition of the IRESSEF as GVN’s newest Center of Excellence.

Released: 6-Jul-2021 5:30 PM EDT
Mount Sinai Research Reveals How the Ebola Virus Manages to Evade the Body’s Immune Defenses
Mount Sinai Health System

Mount Sinai researchers have uncovered the complex cellular mechanisms of Ebola virus, which could help explain its severe toll on humans and identify potential pathways to treatment and prevention. In a study published in mBio, the team reported how a protein of the Ebola virus, VP24, interacts with the double-layered membrane of the cell nucleus (known as the nuclear envelope), leading to significant damage to cells along with virus replication and the propagation of disease.

Released: 17-Jun-2021 2:05 PM EDT
Trojan horses and tunneling nanotubes: Ebola virus research at Texas Biomed gets NIH funding boost
Texas Biomedical Research Institute

Scientists have a general idea of how viruses invade and spread in the body, but the precise mechanisms are actually not well understood, especially when it comes to Ebola virus. Olena Shtanko, Ph.D., a Staff Scientist at the Texas Biomedical Research Institute (Texas Biomed), has received more than $1 million from the National Institutes of Health (NIH) to explore different aspects of Ebola virus infection.

20-Apr-2021 9:00 AM EDT
Researchers Design Sensor for Fast, Inexpensive On-Site Ebola Detection
Federation of American Societies for Experimental Biology (FASEB)

Researchers are developing a new sensor that can detect Ebola in a single drop of blood and provides results in just an hour. With further development, the technology might also enable fast and inexpensive detection of other viruses, including the virus that causes COVID-19.

Released: 20-Apr-2021 1:20 PM EDT
New Tech Makes Detecting Airborne Ebola Virus Possible
Homeland Security's Science And Technology Directorate

&T's National Biodefense Analysis and Countermeasures Center designed and conducted a study to optimize methods for collecting and measuring very small amounts of Ebola virus in the air.

Released: 14-Apr-2021 11:10 AM EDT
Shape-shifting Ebola virus protein exploits human RNA to change shape
La Jolla Institute for Immunology

In a new Cell Reports study, researchers at La Jolla Institute for Immunology demonstrate how Ebola virus has found a different way to get things done. The virus encodes only eight proteins but requires dozens of functions in its lifecycle. The new study shows how one of Ebola virus’s key proteins, VP40, uses molecular triggers in the human cell to transform itself into different tools for different jobs.

Released: 4-Mar-2021 11:55 AM EST
How S&T’s Past Bioagent Research Informs Current and Future Pandemic Response
Homeland Security's Science And Technology Directorate

S&T Past Research with anthrax bacteria, Ebola virus and other pathogens informs current and future pandemic response.

Released: 2-Mar-2021 8:25 AM EST
Vaccine development software shows promise in influenza effort, could help defeat coronavirus
Los Alamos National Laboratory

A novel computer algorithm that could create a broadly reactive influenza vaccine for swine flu also offers a path toward a pan-influenza vaccine and possibly a pan-coronavirus vaccine as well, according to a new paper published in Nature Communications.

Released: 8-Feb-2021 1:05 PM EST
New drug target for Ebola, Marburg viruses
University of Illinois Chicago

Researchers have identified a previously unknown site on the filovirus glycoprotein to which small drug molecules can bind and prevent infection -- blocking both sites may be more a more effective treatment with reduced risk of side effects.

Released: 20-Oct-2020 12:55 PM EDT
Using supercomputers to combat Ebola
University of Delaware

As the world grapples with COVID-19, the Ebola virus is again raging. A research team at University of Delaware is using supercomputers to simulate the inner workings of Ebola (as well as COVID-19), looking at how molecules move, atom by atom, to carry out their functions. Now, they have revealed structural features of the Ebola virus’s protein shell to provide therapeutic targets to destabilize the virus and knock it out with an antiviral treatment.

14-Oct-2020 2:05 PM EDT
Computational Study Reveals How Ebola Nucleocapsid Stabilizes
American Institute of Physics (AIP)

Scientists at the University of Delaware report a computational study of a nucleocapsid found in the Ebola virus and show that the binding of the ssRNA allows the nucleocapsid to maintain its shape and structural integrity.

Released: 26-May-2020 3:00 PM EDT
COVID-19: A wake-up call for the need for new antiviral weapons
Morgridge Institute for Research

Even after heroic medical and societal efforts finally break the back of the current COVID-19 pandemic, the global sigh of relief may not last long. The chilling reality is that viral threats are growing more common. And they’re getting deadlier.

Released: 7-May-2020 6:30 PM EDT
Dearth of Medical Resources in Africa for COVID-19 Reminiscent of Early HIV/AIDS Pandemic
Georgetown University Medical Center

Global health scholars have issued a clarion call about the needless loss of life expected because of a foreseeable prospect of “slow and inadequate access to supplies” to control COVID-19 in sub-Saharan Africa. They say what is unfolding now is similar to when lifesaving diagnostics and treatments came to the region long after they were available elsewhere.

Released: 21-Apr-2020 1:15 PM EDT
The PALM Trial honored with the Society for Clinical Trials’ prestigious David Sackett Trial of the Year Award for 2020
Society for Clinical Trials

Each year since 2008, SCT has awarded the David Sackett Trial of the Year Award to a randomized, controlled trial published (either electronically or in print) in the previous calendar year. The 2020 recipient is Pamoja Tulinde Maisha (PALM [“Together Save Lives”] in the Kiswahili language) trial.

Released: 3-Apr-2020 4:25 PM EDT
UCLA clinical trial tests anti-viral drug remdesivir and other therapies against COVID-19
University of California, Los Angeles (UCLA), Health Sciences

UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate anti-viral drug against COVID-19.

Released: 19-Mar-2020 1:55 PM EDT
Pandemic Panic
University of California, Santa Barbara

After the Ebola virus tore through western Africa in 2015, two UC Santa Barbara researchers studied the xenophobia of the disease generated among people who had almost zero chance of being infected by it.

Released: 2-Mar-2020 2:15 PM EST
Study reveals how drug meant for Ebola may also work against coronaviruses
University of Alberta

A group of University of Alberta researchers who have discovered why the drug remdesivir is effective in treating the coronaviruses that cause Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) expect it might also be effective for treating patients infected with the new COVID-19 strain.

Showing results 1 – 50 of 313